Evolving concepts in the treatment of heart failure: Should new inotropic agents carry promise or paranoia?

Pharmacotherapy

Volumn 16, Issue 2 II, 1996, Pages

  Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; AMRINONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CARDIAC GLYCOSIDE; CYCLIC AMP; DIGOXIN; DOBUTAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENOXIMONE; FLOSEQUINAN; IBOPAMINE; INOTROPIC AGENT; MILRINONE; MYOSIN; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; TROPONIN;

CALCIUM CELL LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; REVIEW;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0029936798     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Young JB, Winters WL, Bourge R, Uretsky BF. Task force 4: function of the heart transplant recipient. American College of Cardiology 24th Bethesda conference: cardiac transplantation. J Am Coll Cardiol 1993;22(1):31-41.
2. Young JB, Pratt CM. Hemodynamic and hormonal alterations in patients with heart failure towards a contemporary definition of heart failure In: Suki WN, ed Seminars in nephrology: the kidney in congestive heart failure. Philadelphia: WB Saunders, 1994:427-40
3. Young JB. Contemporary management of patients with heart failure. Med Clin North Am 1995;79.1171-90.
4. Mann DL, Young JB. Basic mechanism in congestive heart failure: recognizing the role of pro-inflammatory cytokines. Chest 1994;105:897-904
5. Young JB, Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol 1994;43:151-63.
6. Young JB. Reduction of ischemic events with angiotensinconverting enzyme inhibitors: lessons and controversy emerging from recent clinical trials. Cardiovasc Drugs Ther 1995;9:89-131.
7. Young JB. Do digitalis glycosides still have a role in congestive heart failure? Cardiol Clin 1994;12:51-61.
8. Fleischer S, Inui M. Biochemistry and biophysics of excitation-contraction coupling. Annu Rev Biophys Chem 1989;18: 333-64.
9. Uretsky BF, Young JB, Shahidi E, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993;22:955-62.
10. Packer M, Gheorghiade M, Young JB, et al. Randomized, double-blind, placebo-controlled, withdrawal study of digoxin in patients with chronic heart failure treated with converting-enzyme inhibitors N Engl J Med 1993;329:1-7.
11. Massie B, Barrassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1983,71:963-71
12. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstr]. Circulation 1986;74:II-38
13. Narahara KA. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. Am Heart J 1991,121:1471-9
14. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic or diuretic, digoxin and an angiotensin-converting enzyme inhibitor? Circulation 1993;88 492-501.
15. Boots Pharmaceuticals. Letter to physicians. Shreveport, LA, May 24, 1993.
16. Metra M, DeiCas L. Clinical efficacy of ibopamine in patients with chronic heart failure. Clin Cardiol 1995;18(suppl):22-31.
17. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J. Med 1991;325:1468-75.
18. Feldman Am, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure N Engl J Med 1993;329:149-55.
19. The Xamoterol in Severe Heart Failure Study Group, Xamoterol in severe heart failure. Lancet 1990;336.1-6.
20. Parker JO. The effects of oral ibopamine in patients with mild heart failure - a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol 1993;40:221-7.
21. Van Veldhuisen DJ, Man in't Veld AJ, Dunselman PHJM, et al. Double-blind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993;22:1564-73.
22. Chatterjee K. Newer oral inotropic agents: phosphodiesterase inhibitors. Crit Care Med 1990;18 34-53.
23. Stevenson WG, Stevenson LW. Sudden death in heart failure: mechanism and prevention. In: Brunwald E, ed Heart disease, update 1 Philadelphia: WB Saunders, 1995:1-10.
24. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure, results of a multicenter trial. Circulation 1995,85.942-9.
25. Corin WJ, Monrad ES, Strom JA, Giustino S, Sonnenblock ES, Lejemtel T. Flosequinan a vasodilator with positive inotropic activity Am Heart J 1991;121:537-40.